Table 2.

Multivariable-adjusted analysis evaluating potential predictors of recorded outcomes

Covariate at baseline	OH hospitalisation n=504		Unexplained syncope hospitalisation n=524
	Adjusted HR (95% CI)	p Value	Adjusted HR (95% CI)	p Value
Female gender	0.82 (0.67 to 1.01)	0.061	0.81 (0.66 to 0.98)	0.033
Mean BMI, 1-unit increase	0.97 (0.94 to 1.00)	0.025	1.03 (1.00 to 1.05)	0.033
Mean age, 1 year increase	1.11 (1.08 to 1.12)	<0.001	1.07 (1.05 to 1.09)	<0.001
Current cigarette smoking	0.99 (0.77 to 1.26)	0.93	1.10 (0.87 to 1.38)	0.426
Diabetes	1.82 (1.23 to 2.70)	0.003	1.20 (0.79 to 1.84)	0.386
Prevalent CVD	1.30 (0.89 to 1.89)	0.183	1.59 (1.14 to 2.23)	0.007
Prevalent cancer	0.73 (0.48 to 1.11)	0.147	0.75 (0.50 to 1.13)	0.167
Systolic BP, 10 mm Hg increase	1.05 (0.99 to 1.10)	0.099	1.06 (1.01 to 1.12)	0.024
ACE-inhibitor	1.06 (0.65 to 1.73)	0.828	0.80 (0.49 to 1.31)	0.378
Beta-blocker	1.17 (0.87 to 1.58)	0.293	0.92 (0.69 to 1.23)	0.584
Calcium channel blocker	0.74 (0.48 to 1.14)	0.177	1.10 (0.77 to 1.57)	0.589
Diuretic	1.06 (0.74 to 1.53)	0.741	1.77 (1.31 to 2.38)	<0.001
AHT*	1.14 (0.89 to 1.46)	0.304	1.26 (1.00 to 1.59)	0.050

*Excluding the four classes of antihypertensive drugs from the model.

AHT, antihypertensive treatment; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; OH, orthostatic hypotension.